[ Inside the business ]

VTRS stock analysis

VTRS · Viatris Inc

Pharmaceutical preparations. Shrinking 0%. Loses 0¢ on every dollar.

Watch: growth that has stopped speeding up.

The future, in 7 questions

Priced in: 0.6× sales in 5 yrs. Evidence: sales −0% · loss growing.

01 What's priced in?0.6× sales in 5 yrs
Sales now$14.7B
Needed in 5 yrs$9.1B
02 Is the wave rising?No Radar technology matched

Not among the companies mentioning Radar's technologies most.

03 Will customers keep buying?Sales −0%, steady
Ameri Source Bergen 11%Everyone else
Sales −0%, steady
04 Is it scarce?No
PricingBacklogPrepaidSell-outTight
05 More profit per sale?Loss growing: −0¢ per $1
'21'22'23'24'25−0¢
Before running costs: 40% → 35%
06 Can it fund itself?Pays its own way
05 yrsself-funded
Shares Not availableDebt $13.3B
07 What could break it?2 to watch
  • Growth slowing
  • Moves strongly with the S&P 500

From SEC filings, price and Radar. Not advice.

The record

Early signals

Growth slowing.

Sales growth +8%, +5%, then −0% vs. a year ago. New filings show a new major deal.

What could go wrong

Few warning signs.

It has moved 1.1× the market. In the 2022 rate shock it fell 35% while the market fell 24%. Debt is heavy.

Speculative check

Not classified.

Not Self-funding because of: operating loss, net loss, loss in the latest quarter, and more.

What they sell

65% Brands.

Brands 65% · Lipitor ® 12% · Norvasc ® 5% · Lyrica ® 3% · other

Where each dollar goes

0¢ loss.

65¢ to make what it sells, 35¢ on research and overhead, nothing left over. Revenue $14.7B in the last 12 months.

Its market

1.5× the economy.

The government expects its industry, pharmaceutical and medicine manufacturing, to grow 3.0% a year to 2035, vs. 2.0% for the whole economy.

Market size and share

Your call.

There's no official size for its market. Enter one you trust to see its share, and slide to see what a bigger share would mean.

Life cycle

Shake-out.

Its cash flows are mixed, typical of a company in transition.

Earnings quality

Clean.

Its numbers don't resemble those of past manipulators.

Competitive advantage

1 of 8 years.

Returns beat its 6.7% cost of capital in 1 of the last 8 years. Gross margin went from 35% to 35%.

Future bets

7% on research.

$1B a year on R&D. $375M on equipment and buildings.

All figures from Viatris Inc's SEC filings (EDGAR) unless tagged otherwise. Educational only, not investment advice.